drugset
drugset / Trial / NCT02566759

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

NCT02566759 ↗

Phase 1 Terminated 110 enrolled Neurocrine Biosciences Takeda · collab
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.

Timeline

Start
2015-09-23
Primary completion
2016-06-09
Completion
2016-07-12

Outcome

Outcome not reported

Stopped: “The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Luvadaxistat Small molecule 10 mg Oral
Subject Luvadaxistat Small molecule 30 mg Oral
Subject Luvadaxistat Small molecule 100 mg Oral
Subject Luvadaxistat Small molecule 200 mg Oral
Subject Luvadaxistat Small molecule 250 mg Oral
Subject Luvadaxistat Small molecule 400 mg Oral
Subject Luvadaxistat Small molecule 500 mg Oral
Subject Luvadaxistat Small molecule 750 mg Oral

Indications

No indication recorded.